ArticleScientific reports2025
Comprehensive analysis of cuproptosis and m6A-Target gene signatures for diagnostic significance and immune microenvironment characterization in polycystic ovary syndrome.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Copper Dyshomeostasis, Redox Buffering and Immune Aging Converge on Cuproptosis in Age-Related Diseases.Antioxidants (Basel, Switzerland) · 2026Review
- Integrative bioinformatics, single-cell and experimental evidence for a BPA-m6A-apoptosis axis in granulosa cell dysfunction in polycystic ovary syndrome.Journal of ovarian research · 2026Article
- Interpreting the molecular and cellular landscape of PCOS through bulk transcriptomics, single-cell transcriptomics and machine learning.Journal of ovarian research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Polycystic Ovary Syndrome (PCOS) lacks specific biomarkers for early diagnosis. Recent evidence implicates cuproptosis, a copper-induced regulated cell death pathway, and N6-methyladenosine (m6A) RNA modifications in metabolic and inflammatory processes central to PCOS pathogenesis. This study aimed to construct integrated diagnostic signatures based on cuproptosis- and m6A-related gene expression. Transcriptome data from GEO datasets (GSE95728, GSE106724, GSE114419) comprising 28 PCOS and 22 control granulosa cell samples were merged and batch-corrected. Differentially expressed genes (DEGs) overlapping with curated cuproptosis-related and m6A-target gene sets were identified. LASSO regression was applied to generate diagnostic models based on selected DEGs: CASK, AGMAT, NEDD4, and PTGES3 (cuproptosis); CLDN1, ACLY, and DDX3X (m6A). The combined model achieved excellent diagnostic accuracy (AUC up to 0.960), validated in an independent dataset (GSE168404). ssGSEA analysis revealed immune dysregulation involving dendritic cells, T cell subsets, and myeloid-derived suppressor cells, which correlated with risk scores. Drug-gene association analysis via CellMiner indicated therapeutic relevance of targets such as ACLY and CLDN1 (Vinblastine), as well as CASK and CLDN1 (XAV-939). qRT-PCR validation in granulosa cells from 5 PCOS patients and 5 controls confirmed gene expression trends. These findings suggest cuproptosis- and m6A-based signatures may enable accurate PCOS diagnosis and guide individualized immunomodulatory strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.